Form 8-K - Current report:
SEC Accession No. 0001437749-22-002101
Filing Date
2022-02-01
Accepted
2022-02-01 16:30:35
Documents
14
Period of Report
2022-01-31
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20220131_8k.htm   iXBRL 8-K 29124
2 EXHIBIT 3.1 ex_330469.htm EX-3.1 7026
  Complete submission text file 0001437749-22-002101.txt   177905

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nby-20220131.xsd EX-101.SCH 3584
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20220131_def.xml EX-101.DEF 12183
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20220131_lab.xml EX-101.LAB 16395
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20220131_pre.xml EX-101.PRE 12453
8 EXTRACTED XBRL INSTANCE DOCUMENT nby20220131_8k_htm.xml XML 2777
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 22579313
SIC: 2834 Pharmaceutical Preparations